Amgen Inc (AMGN) stock
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3026% above fair value
$443.89−14.04 (-3.07%)
Close on Nov 18, 2026Market cap $239.98BP/E 25.7Yield 2.18%
Amgen total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Amgen's total debt was $54.01B at Sep 30, 2026. For fiscal 2025 it was $54.60B, down 9.1% from the year before. Over ten years it grew 5.7% a year on average. The highest annual figure on record is $64.61B in fiscal 2023.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $54.60B | -9.1% |
| FY2024 | Dec 31, 2024 | $60.10B | -7.0% |
| FY2023 | Dec 31, 2023 | $64.61B | +65.9% |
| FY2022 | Dec 31, 2022 | $38.95B | +16.9% |
| FY2021 | Dec 31, 2021 | $33.31B | +1.0% |
| FY2020 | Dec 31, 2020 | $32.99B | +10.3% |
| FY2019 | Dec 31, 2019 | $29.90B | -11.9% |
| FY2018 | Dec 31, 2018 | $33.93B | -4.0% |
| FY2017 | Dec 31, 2017 | $35.34B | +2.2% |
| FY2016 | Dec 31, 2016 | $34.60B | +10.1% |
| FY2015 | Dec 31, 2015 | $31.43B | +2.3% |
| FY2014 | Dec 31, 2014 | $30.72B | -4.4% |
| FY2013 | Dec 31, 2013 | $32.13B | +33.7% |
| FY2012 | Dec 31, 2012 | $24.03B | +12.6% |
| FY2011 | Dec 31, 2011 | $21.34B | +96.3% |
| FY2010 | Dec 31, 2010 | $10.87B | +2.6% |
| FY2009 | Dec 31, 2009 | $10.60B | +158.9% |
| FY2008 | Dec 31, 2008 | $4.10B | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $54.01B | -1.1% |
| Q2 FY2026 | Jun 30, 2026 | $57.30B | +2.0% |
| Q1 FY2026 | Mar 31, 2026 | $57.32B | -0.1% |
| Q4 FY2025 | Dec 31, 2025 | $54.60B | -9.1% |
| Q3 FY2025 | Sep 30, 2025 | $54.59B | -9.6% |
| Q2 FY2025 | Jun 30, 2025 | $56.20B | -10.3% |
| Q1 FY2025 | Mar 31, 2025 | $57.38B | -10.4% |
| Q4 FY2024 | Dec 31, 2024 | $60.10B | -7.0% |
| Q3 FY2024 | Sep 30, 2024 | $60.40B | -0.1% |
| Q2 FY2024 | Jun 30, 2024 | $62.65B | +1.8% |
| Q1 FY2024 | Mar 31, 2024 | $64.02B | +3.9% |
| Q4 FY2023 | Dec 31, 2023 | $64.61B | +65.9% |
| Q3 FY2023 | Sep 30, 2023 | $60.47B | +56.2% |
| Q2 FY2023 | Jun 30, 2023 | $61.54B | +68.5% |
| Q1 FY2023 | Mar 31, 2023 | $61.60B | +67.1% |
| Q4 FY2022 | Dec 31, 2022 | $38.95B | +16.9% |
| Q3 FY2022 | Sep 30, 2022 | $38.70B | +3.0% |
| Q2 FY2022 | Jun 30, 2022 | $36.52B | +11.7% |
| Q1 FY2022 | Mar 31, 2022 | $36.85B | +11.7% |
| Q4 FY2021 | Dec 31, 2021 | $33.31B | -2.9% |
| Q3 FY2021 | Sep 30, 2021 | $37.58B | +9.8% |
| Q1 FY2021 | Mar 31, 2021 | $32.69B | +2.6% |
| Q4 FY2020 | Dec 31, 2020 | $32.99B | +10.3% |
| Q3 FY2020 | Sep 30, 2020 | $34.29B | +12.0% |
| Q2 FY2020 | Jun 30, 2020 | $34.22B | +3.6% |
| Q1 FY2020 | Mar 31, 2020 | $31.85B | -6.1% |
| Q4 FY2019 | Dec 31, 2019 | $29.90B | -13.1% |
| Q2 FY2019 | Jun 30, 2019 | $30.61B | -11.3% |
| Q1 FY2019 | Mar 31, 2019 | $33.02B | -7.1% |
| Q4 FY2018 | Dec 31, 2018 | $33.93B | -4.0% |
| Q3 FY2018 | Sep 30, 2018 | $34.43B | -3.8% |
| Q2 FY2018 | Jun 30, 2018 | $34.50B | -1.6% |
| Q1 FY2018 | Mar 31, 2018 | $35.54B | +4.3% |
| Q4 FY2017 | Dec 31, 2017 | $35.34B | +2.2% |
| Q3 FY2017 | Sep 30, 2017 | $35.78B | +1.3% |
| Q2 FY2017 | Jun 30, 2017 | $35.06B | +5.5% |
| Q1 FY2017 | Mar 31, 2017 | $34.09B | – |
| Q4 FY2016 | Dec 31, 2016 | $34.60B | – |
| Q3 FY2016 | Sep 30, 2016 | $35.32B | – |
| Q2 FY2016 | Jun 30, 2016 | $33.22B | – |
See a number that looks wrong?